COMPASS Pathways (NASDAQ:CMPS) Reaches New 1-Year High – Here’s Why

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) reached a new 52-week high during trading on Tuesday . The stock traded as high as $8.80 and last traded at $7.7150, with a volume of 9893874 shares traded. The stock had previously closed at $5.81.

COMPASS Pathways News Summary

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: Late‑stage trial met main goal — Reuters reports Compass’s psilocybin depression therapy achieved its primary endpoint in a late‑stage study, a major clinical milestone that can materially de‑risk the program and improve prospects for regulatory progress. Article Title
• Positive Sentiment: Company to disclose additional Phase 3 data — Compass said it will announce new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006), providing more readouts that could further move the stock depending on results. Article Title
• Positive Sentiment: Market reaction and media coverage — Multiple outlets covered the trial success and timeline, and pre‑market headlines noted a strong price move, which likely amplified buying interest and momentum. Article Title
• Positive Sentiment: Additional media on late‑stage success — Coverage emphasises broader industry implications for psychedelic therapies, which can attract speculative and institutional interest. Article Title
• Positive Sentiment: Unusually large call buying — Traders bought ~10,094 call options (≈+290% vs. typical volume), indicating speculative bullish positioning ahead of and after the clinical announcements. This can amplify intraday moves and implied volatility.
• Neutral Sentiment: Analyst/forecast coverage — Recent firm coverage and forecasts (e.g., Lifesci Capital commentary) are available but reflect forward estimates; they may influence sentiment but are not primary drivers compared with trial news. Article Title
• Neutral Sentiment: Short‑interest report unclear — Recent short‑interest data appears anomalous/zeroed in the report provided; not actionable without clearer reporting.
• Negative Sentiment: Clinical success ≠ approval/commercialization — While the readout is positive, regulatory approval, labeling, reimbursement, manufacturing scale and commercial adoption remain uncertain; investors should expect volatility and potential setbacks as the program moves through formal regulatory review.

Wall Street Analyst Weigh In

CMPS has been the subject of a number of recent analyst reports. Morgan Stanley lifted their price objective on COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada lifted their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Lifesci Capital upgraded shares of COMPASS Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Compass Point set a $15.00 target price on shares of COMPASS Pathways in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, COMPASS Pathways currently has an average rating of “Moderate Buy” and a consensus price target of $16.11.

COMPASS Pathways Stock Performance

The stock has a 50 day simple moving average of $6.74 and a 200 day simple moving average of $5.87. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. The company has a market cap of $779.59 million, a price-to-earnings ratio of -2.98 and a beta of 1.92.

Institutional Trading of COMPASS Pathways

Large investors have recently bought and sold shares of the company. Royal Bank of Canada raised its stake in shares of COMPASS Pathways by 4.6% during the fourth quarter. Royal Bank of Canada now owns 181,168 shares of the company’s stock valued at $1,250,000 after purchasing an additional 7,966 shares during the period. Graham Capital Management L.P. grew its holdings in COMPASS Pathways by 147.2% during the 4th quarter. Graham Capital Management L.P. now owns 36,144 shares of the company’s stock valued at $249,000 after purchasing an additional 21,520 shares in the last quarter. Magnetar Financial LLC purchased a new stake in COMPASS Pathways during the 4th quarter worth $91,000. Persistent Asset Partners Ltd acquired a new position in COMPASS Pathways in the 4th quarter worth $38,000. Finally, Squarepoint Ops LLC purchased a new position in COMPASS Pathways in the 4th quarter valued at about $131,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.